IN2014DN09776A - - Google Patents
Info
- Publication number
- IN2014DN09776A IN2014DN09776A IN9776DEN2014A IN2014DN09776A IN 2014DN09776 A IN2014DN09776 A IN 2014DN09776A IN 9776DEN2014 A IN9776DEN2014 A IN 9776DEN2014A IN 2014DN09776 A IN2014DN09776 A IN 2014DN09776A
- Authority
- IN
- India
- Prior art keywords
- soluble
- subject
- level
- methods
- biological sample
- Prior art date
Links
- 206010065341 Ventricular tachyarrhythmia Diseases 0.000 abstract 3
- 239000012472 biological sample Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 206010047302 ventricular tachycardia Diseases 0.000 abstract 3
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 230000008672 reprogramming Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/3627—Heart stimulators for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/38—Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
- A61N1/39—Heart defibrillators
- A61N1/3956—Implantable devices for applying electric shocks to the heart, e.g. for cardioversion
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Surgery (AREA)
- Artificial Intelligence (AREA)
- Medical Informatics (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Signal Processing (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261649202P | 2012-05-18 | 2012-05-18 | |
| PCT/US2013/041686 WO2013173778A1 (en) | 2012-05-18 | 2013-05-17 | Methods for treating or predicting risk of a ventricular tachyarrhythmia event |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09776A true IN2014DN09776A (forum.php) | 2015-07-31 |
Family
ID=49584355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9776DEN2014 IN2014DN09776A (forum.php) | 2012-05-18 | 2014-11-18 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20130345805A1 (forum.php) |
| EP (2) | EP3434260A1 (forum.php) |
| JP (2) | JP6302896B2 (forum.php) |
| CN (2) | CN109212223B (forum.php) |
| AU (2) | AU2013262515B2 (forum.php) |
| CA (1) | CA2873896A1 (forum.php) |
| ES (1) | ES2709697T3 (forum.php) |
| HK (1) | HK1208624A1 (forum.php) |
| IN (1) | IN2014DN09776A (forum.php) |
| MX (1) | MX357740B (forum.php) |
| WO (1) | WO2013173778A1 (forum.php) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002218026A1 (en) | 2000-11-09 | 2002-05-21 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| DK2336359T3 (en) | 2002-05-09 | 2016-05-30 | Brigham & Womens Hospital | 1L1RL-1 as cardiovascular disease marker |
| EP2386860B1 (en) | 2006-04-24 | 2014-11-05 | Critical Care Diagnostics, Inc. | Predicting mortality and detecting severe disease |
| WO2007143295A2 (en) * | 2006-04-27 | 2007-12-13 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
| ES2380711T3 (es) | 2006-05-01 | 2012-05-17 | Critical Care Diagnostics, Inc. | Diagnóstico de enfermedades cardiovasculares |
| ES2443125T3 (es) | 2008-04-18 | 2014-02-17 | Critical Care Diagnostics, Inc. | Predicción del riesgo a sufrir episodios cardíacos adversos graves |
| RU2625014C2 (ru) * | 2010-04-09 | 2017-07-11 | Критикал Кэа Дайэгностикс, Инк. | Антитела против растворимого st-2 человека и способы анализа |
| WO2012141844A2 (en) | 2011-03-17 | 2012-10-18 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
| ES2611403T3 (es) | 2011-07-18 | 2017-05-08 | Critical Care Diagnostics, Inc. | Procedimientos de tratamiento de enfermedades cardiovasculares y de predicción de la eficacia de terapia de ejercicio |
| WO2013116547A1 (en) * | 2012-01-31 | 2013-08-08 | Cardiac Pacemakers, Inc. | Implantable device and methods for diagnosing heart failure using biomarker panel data |
| JP2015510416A (ja) | 2012-01-31 | 2015-04-09 | カーディアック ペースメイカーズ， インコーポレイテッド | バイオマーカーパネルデータを使用して、心臓再同期装置／治療を制御するシステム及び方法 |
| CA2873896A1 (en) * | 2012-05-18 | 2013-11-21 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of a ventricular tachyarrhythmia event |
| MX382403B (es) | 2012-08-16 | 2025-03-13 | Critical Care Diagnostics Inc | Métodos para predecir el riesgo de desarrollar hipertensión. |
| HK1212057A1 (en) | 2012-08-21 | 2016-06-03 | 重症监护诊断股份有限公司 | Multimarker risk stratification |
| US10670611B2 (en) | 2014-09-26 | 2020-06-02 | Somalogic, Inc. | Cardiovascular risk event prediction and uses thereof |
| US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| US10188863B2 (en) * | 2015-02-26 | 2019-01-29 | Medtronic, Inc. | Therapy program selection for electrical stimulation therapy based on a volume of tissue activation |
| JP7009977B2 (ja) * | 2017-12-25 | 2022-01-26 | 国立大学法人東海国立大学機構 | 被検体の血中ｖｅｇｆ－ａに関する測定値を用いた心疾患の重症度及び予後予測を行うための方法、装置及びコンピュータプログラム |
| WO2020097190A1 (en) * | 2018-11-06 | 2020-05-14 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method of personalized treatment for cardiomyopathy and heart failure and associated diseases by measuring edema and cachexia/sarcopenia |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001070817A1 (fr) | 2000-03-21 | 2001-09-27 | Medical & Biological Laboratories Co., Ltd. | Anticorps monoclonal et methode et kit d'immunodosage de st2 humaine soluble l'utilisant |
| AU2002218026A1 (en) | 2000-11-09 | 2002-05-21 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| DK2336359T3 (en) | 2002-05-09 | 2016-05-30 | Brigham & Womens Hospital | 1L1RL-1 as cardiovascular disease marker |
| WO2005043123A2 (en) | 2003-10-31 | 2005-05-12 | Queststar Medical, Inc. | System and apparatus for body fluid analysis using surface-textured optical materials |
| WO2005078452A1 (en) | 2004-02-05 | 2005-08-25 | Medtronic, Inc. | Methods and apparatus for identifying patients at risk for life threatening arrhythmias |
| EP2386860B1 (en) | 2006-04-24 | 2014-11-05 | Critical Care Diagnostics, Inc. | Predicting mortality and detecting severe disease |
| WO2007143295A2 (en) | 2006-04-27 | 2007-12-13 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
| ES2380711T3 (es) | 2006-05-01 | 2012-05-17 | Critical Care Diagnostics, Inc. | Diagnóstico de enfermedades cardiovasculares |
| EP2995951B1 (en) | 2006-05-02 | 2019-02-13 | Critical Care Diagnostics, Inc. | Method for selecting treatment based on differential diagnosis between pulmonary and cardiovascular disease |
| EP1884777A1 (en) * | 2006-08-04 | 2008-02-06 | Medizinische Hochschule Hannover | Means and methods for assessing the risk of cardiac interventions based on GDF-15 |
| EP2315034A3 (en) | 2006-08-04 | 2011-08-17 | Medizinische Hochschule Hannover | Means and methods for assessing the risk of cardiac interventions based on GDF-15 |
| CN103123359B (zh) * | 2007-08-03 | 2015-07-29 | B.R.A.H.M.S有限公司 | 降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用 |
| US20090092998A1 (en) * | 2007-09-11 | 2009-04-09 | The United States Of America Department Of Veterans Affairs | Marker for arrhythmia risk |
| EP2107377A1 (en) * | 2008-04-04 | 2009-10-07 | BRAHMS Aktiengesellschaft | Pro-endothelin-1 levels for the prediction of risk of tachyarrhytmic events |
| ES2443125T3 (es) | 2008-04-18 | 2014-02-17 | Critical Care Diagnostics, Inc. | Predicción del riesgo a sufrir episodios cardíacos adversos graves |
| GB0818650D0 (en) * | 2008-10-10 | 2008-11-19 | Uni I Oslo | Methods |
| EP3178846B1 (en) * | 2010-02-17 | 2018-08-22 | Cedars-Sinai Medical Center | Novel phosphorylation of cardiac troponin i as a monitor for cardiac injury |
| RU2625014C2 (ru) | 2010-04-09 | 2017-07-11 | Критикал Кэа Дайэгностикс, Инк. | Антитела против растворимого st-2 человека и способы анализа |
| WO2012141844A2 (en) | 2011-03-17 | 2012-10-18 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
| ES2611403T3 (es) | 2011-07-18 | 2017-05-08 | Critical Care Diagnostics, Inc. | Procedimientos de tratamiento de enfermedades cardiovasculares y de predicción de la eficacia de terapia de ejercicio |
| CA2873896A1 (en) * | 2012-05-18 | 2013-11-21 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of a ventricular tachyarrhythmia event |
| MX382403B (es) | 2012-08-16 | 2025-03-13 | Critical Care Diagnostics Inc | Métodos para predecir el riesgo de desarrollar hipertensión. |
| HK1212057A1 (en) | 2012-08-21 | 2016-06-03 | 重症监护诊断股份有限公司 | Multimarker risk stratification |
-
2013
- 2013-05-17 CA CA2873896A patent/CA2873896A1/en not_active Abandoned
- 2013-05-17 CN CN201810869357.1A patent/CN109212223B/zh not_active Expired - Fee Related
- 2013-05-17 EP EP18193293.0A patent/EP3434260A1/en not_active Withdrawn
- 2013-05-17 MX MX2014013995A patent/MX357740B/es active IP Right Grant
- 2013-05-17 HK HK15109315.2A patent/HK1208624A1/xx unknown
- 2013-05-17 JP JP2015512902A patent/JP6302896B2/ja not_active Expired - Fee Related
- 2013-05-17 US US13/897,249 patent/US20130345805A1/en not_active Abandoned
- 2013-05-17 EP EP13790571.7A patent/EP2849729B1/en not_active Not-in-force
- 2013-05-17 CN CN201380037345.8A patent/CN104507383B/zh not_active Expired - Fee Related
- 2013-05-17 WO PCT/US2013/041686 patent/WO2013173778A1/en active Application Filing
- 2013-05-17 ES ES13790571T patent/ES2709697T3/es active Active
- 2013-05-17 AU AU2013262515A patent/AU2013262515B2/en not_active Ceased
-
2014
- 2014-11-18 IN IN9776DEN2014 patent/IN2014DN09776A/en unknown
-
2016
- 2016-12-06 US US15/370,049 patent/US10408845B2/en not_active Expired - Fee Related
-
2018
- 2018-03-05 JP JP2018038175A patent/JP6600709B2/ja not_active Expired - Fee Related
- 2018-06-12 AU AU2018204145A patent/AU2018204145A1/en not_active Abandoned
-
2019
- 2019-09-06 US US16/563,510 patent/US11340236B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2849729A4 (en) | 2016-01-20 |
| HK1208624A1 (en) | 2016-03-11 |
| AU2013262515A1 (en) | 2014-12-04 |
| US11340236B2 (en) | 2022-05-24 |
| CN104507383B (zh) | 2018-08-28 |
| CN109212223B (zh) | 2021-11-12 |
| EP2849729A1 (en) | 2015-03-25 |
| JP6302896B2 (ja) | 2018-03-28 |
| JP6600709B2 (ja) | 2019-10-30 |
| CN104507383A (zh) | 2015-04-08 |
| EP2849729B1 (en) | 2018-11-14 |
| JP2015520371A (ja) | 2015-07-16 |
| US10408845B2 (en) | 2019-09-10 |
| AU2018204145A1 (en) | 2018-06-28 |
| AU2013262515B2 (en) | 2018-03-15 |
| US20190391162A1 (en) | 2019-12-26 |
| MX2014013995A (es) | 2015-09-04 |
| US20170146552A1 (en) | 2017-05-25 |
| ES2709697T3 (es) | 2019-04-17 |
| JP2018119976A (ja) | 2018-08-02 |
| MX357740B (es) | 2018-07-23 |
| CN109212223A (zh) | 2019-01-15 |
| US20130345805A1 (en) | 2013-12-26 |
| EP3434260A1 (en) | 2019-01-30 |
| CA2873896A1 (en) | 2013-11-21 |
| WO2013173778A1 (en) | 2013-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN09776A (forum.php) | ||
| MX362514B (es) | Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato. | |
| AU2017225061B2 (en) | Biomarkers and methods of treating PD-1 and PD-L1 related conditions | |
| MX2022006075A (es) | Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer. | |
| MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
| AU2017245629A1 (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| EP3236262A3 (en) | Surrogate functional diagnostics test for cancer | |
| EP4321866A3 (en) | Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers | |
| MX2014005800A (es) | Mutaciones del receptor notch humano y su uso. | |
| MX2017014381A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| WO2016201450A3 (en) | Cancer treatment and diagnosis | |
| HK1203971A1 (en) | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling | |
| WO2019090347A8 (en) | Adenosine pathway inhibitors for cancer treatment | |
| WO2015094996A3 (en) | Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists | |
| WO2015158652A8 (en) | S100p and hyluronic acid as biomarkers for metastatic breast cancer | |
| WO2015169973A3 (de) | Markersequenzen zur diagnose und stratifizierung von systemische sklerose patienten | |
| AU2018275891A1 (en) | Articles of manufacture and methods related to toxicity associated with cell therapy | |
| WO2015006657A8 (en) | Method for the diagnosis and prognosis of cancer | |
| WO2014023808A3 (en) | Method for evaluating a cancer patient for propensity to respond to a therapy | |
| WO2017053763A3 (en) | ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC) | |
| Crespo-Leiro et al. | Analysis of donor-derived cell-free DNA with 3 year outcomes in heart transplant recipients | |
| EP2148934A4 (en) | MATRIX MARKER MODEL AND METHOD FOR THE TEST AND TREATMENT OF ARTHRITIS AND RELATED DISEASES | |
| EP2846285A3 (en) | Risk stratification of suspected AMI patients | |
| WO2012064835A3 (en) | Biomarkers and therapeutic targets for treating cardiomyopathies and congestive heart failure | |
| Gopinath et al. | Automated segmentation of ELA cancer cells in microscopic images for evaluating the cytotoxic effect of selected medicinal plants |